One pioneer study demonstrated that blocking CXCR2 disrupted PMN-MDSC trafficking to tumor sites and sensitized the tumors to anti-PD-1 treatment in mice;7 however, this approach specifically targeted PMN-MDSCs but not M-MDSCs and TAMs. This evidence concerns the gene CXCR2 and neoplasm.